<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="./10_1101_2020_04_07_024455v1/results/search/disease/results.xml">
  <result pre="the cytokine storm has been associated with increased risk of" exact="acute respiratory distress syndrome," post="myocardial damage, and death. However, the therapeutic value of"/>
  <result pre="to drive mortality during severe respiratory viral infections, such as" exact="influenza" post="( 1 ) - including the 1918 Spanish flu"/>
  <result pre="to a cascade of events involving a cytokine storm and" exact="acute respiratory distress syndrome" post="(ARDS), often accompanied by myocardial damage and multiple organ"/>
  <result pre="and cytokine production that is approved for the treatment of" exact="rheumatoid arthritis" post="and systemic lupus erythematosus ( 10, 11 ), is"/>
  <result pre="cytokine production that is approved for the treatment of rheumatoid" exact="arthritis" post="and systemic lupus erythematosus ( 10, 11 ), is"/>
  <result pre="that is approved for the treatment of rheumatoid arthritis and" exact="systemic lupus erythematosus" post="( 10, 11 ), is also being testing in"/>
  <result pre="is approved for the treatment of rheumatoid arthritis and systemic" exact="lupus erythematosus" post="( 10, 11 ), is also being testing in"/>
  <result pre="of neurotoxic tryptophan catabolites ( 14 ), and 3) widespread" exact="hypersensitivity" post="to IFN stimulation across the human immune system ("/>
  <result pre="mice overexpress Ifnrs in all immune cell types tested, display" exact="hypersensitivity" post="to Type I and Type II IFN stimulation, overproduce"/>
  <result pre="T-test. *p&amp;lt;;0.05, **p&amp;lt;;0.01, ***p&amp;lt;;0.001, ****p&amp;lt;;0.0001. In order to determine whether" exact="hypersensitivity" post="was restricted to TLR3 agonists or more broadly observed"/>
  <result pre="and dehydration, and is commonly employed as a model of" exact="psoriasis" post="( 21 ). Imiquimod treatment caused significant weight loss"/>
  <result pre="( Figure 2G,H ). Altogether, these results indicate that the" exact="hypersensitivity" post="to IFN stimulation observed at the cellular level in"/>
  <result pre="diverse medical conditions: Jakafi/Ruxolitinib, a JAK1/2 inhibitor approved for myelofibrosis," exact="polycythemia" post="vera, and graft-versus-host-disease; Xeljanz/Tofacitinib, a JAK1/3 inhibitor approved for"/>
  <result pre="polycythemia vera, and graft-versus-host-disease; Xeljanz/Tofacitinib, a JAK1/3 inhibitor approved for" exact="rheumatoid arthritis," post="psoriatic arthritis and ulcerative colitis; Olumiant/Baricitinib, a JAK1/2 inhibitor"/>
  <result pre="and graft-versus-host-disease; Xeljanz/Tofacitinib, a JAK1/3 inhibitor approved for rheumatoid arthritis," exact="psoriatic arthritis" post="and ulcerative colitis; Olumiant/Baricitinib, a JAK1/2 inhibitor approved for"/>
  <result pre="graft-versus-host-disease; Xeljanz/Tofacitinib, a JAK1/3 inhibitor approved for rheumatoid arthritis, psoriatic" exact="arthritis" post="and ulcerative colitis; Olumiant/Baricitinib, a JAK1/2 inhibitor approved for"/>
  <result pre="a JAK1/3 inhibitor approved for rheumatoid arthritis, psoriatic arthritis and" exact="ulcerative colitis;" post="Olumiant/Baricitinib, a JAK1/2 inhibitor approved for rheumatoid arthritis; and"/>
  <result pre="arthritis and ulcerative colitis; Olumiant/Baricitinib, a JAK1/2 inhibitor approved for" exact="rheumatoid arthritis;" post="and Rinvoq/Upadacitinib, a JAK1 inhibitor also approved for rheumatoid"/>
  <result pre="rheumatoid arthritis; and Rinvoq/Upadacitinib, a JAK1 inhibitor also approved for" exact="rheumatoid arthritis." post="Many JAK1- specific inhibitors are currently being developed and"/>
  <result pre=", Z. Q. Yang , The cytokine storm of severe" exact="influenza" post="and development of immunomodulatory therapy. Cell Mol Immunol 13,"/>
  <result pre=", D. Hober , L. H. Kasper , Confronting potential" exact="influenza" post="A (H5N1) pandemic with better vaccines. Emerg Infect Dis"/>
  <result pre="Design and validation of a histological scoring system for nonalcoholic" exact="fatty liver disease." post="Hepatology 41, 1313– 1321 ( 2005). OpenUrl CrossRef PubMed"/>
  <result pre="and validation of a histological scoring system for nonalcoholic fatty" exact="liver disease." post="Hepatology 41, 1313– 1321 ( 2005). OpenUrl CrossRef PubMed"/>
 </snippets>
</snippetsTree>
